PRELP and urinary bladder carcinoma: In this sense, it has been revealed that PRELP interacts with TGFβ1, leading to the suppression of canonical SMAD signal transduction13,16 and suggested that PRELP suppresses bladder cancer progression by reversing the epithelial-mesenchymal transition through inhibition of TGFβ1 signaling pathway13.